Moreover, as anti-CTLA-4 treatment has recently been shown to broaden the T-cell repertoire in melanoma patients10, we wanted to assess whether CTLA-4-blocking primes and gives rise to T-cell responses against predicted antigen candidates that are not present in untreated tumour-bearing animals. This evidence concerns the gene CTLA4 and melanoma.